The ANGPTL3/8 complex inhibits LPL 100-fold more potently and circulates at much lower levels than ANGPTL3 alone [40], making it an interesting potential therapeutic target for the treatment of HTG and hypercholesterolemia. Here, ANGPTL3 is linked to familial hypercholesterolemia.